Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
Chordate Medical Holding AB (OSTO:CMH) EPS (Diluted) Explanation
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Chordate Medical Holding AB EPS (Diluted) Related Terms
Chordate Medical Holding AB EPS (Diluted) Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:CMH vs ABT, SYK, MDT: EPS (Diluted) Comparison
For the Medical Devices subindustry, Chordate Medical Holding AB's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chordate Medical Holding AB PE Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Chordate Medical Holding AB's PE Ratio distribution charts can be found below:
* The bar in red indicates where Chordate Medical Holding AB's PE Ratio falls into.
Chordate Medical Holding AB EPS (Diluted) Calculation
EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.
EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-18.76
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chordate Medical Holding AB (OSTO:CMH) has a EPS (Diluted) of kr-18.76 as of Jun. 2025. Earnings per share (diluted) equals net income divided by the diluted average shares outstanding. View historical data on Chordate Medical Holding AB and its competitors.
Is Chordate Medical Holding AB's EPS (Diluted) too high?
Chordate Medical Holding AB's current EPS (Diluted) is kr-18.76. Overall, Chordate Medical Holding AB has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Chordate Medical Holding AB's EPS (Diluted) compare to ABT and SYK?
Chordate Medical Holding AB's EPS (Diluted) of kr-18.76 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Diluted) for a Medical Devices & Instruments company?
A good EPS (Diluted) depends on the Medical Devices & Instruments industry context. However, EPS (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Diluted) mean?
A high EPS (Diluted) can signal that a stock is expensive relative to its fundamentals. Earnings per share (diluted) equals net income divided by the diluted average shares outstanding. View historical data on Chordate Medical Holding AB and its competitors. Chordate Medical Holding AB's current EPS (Diluted) is kr-18.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chordate Medical Holding AB stock overvalued right now?
Chordate Medical Holding AB (OSTO:CMH) has a current EPS (Diluted) of kr-18.76. The current EPS (Diluted) is kr-18.76. Chordate Medical Holding AB's overall GF Score™ is 46/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Diluted) calculated?
EPS (Diluted) is calculated from a company's financial statements. For Chordate Medical Holding AB (OSTO:CMH), the current EPS (Diluted) is kr-18.76 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Chordate Medical Holding AB is a medical technology company that has developed patented and CE-marked a new nerve-modulating treatment technology for chronic nasal congestion and chronic migraine. The company sells its products in Selected European markets, Israel, and Saudi Arabia. The company's product range is based on the CE-marked treatment units Chordate System S100 and S120 for rhinitis and S220 for migraine, registered for the indications of preventive treatment of chronic migraine and chronic rhinitis and use on patients. The company sells its product system, including treatments, through distributors to clinics and hospitals in its primary markets.
46GF Score
Get the complete analysis for OSTO:CMH
EPS (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:CMH has been successfully added to your 
